arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

BIOXYTRAN, INC

BIXT
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
27 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, BIOXYTRAN, INC shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC None
FCF / Share $-0.01 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$191.08K
↓ -22.5% —
Net Income Profit after all expenses
$-2.12M
↑ +10.3% —
Operating Margin Operating profit as % of sales
-162.5%
↑ +40.3% —
FCF / Share Free cash flow per share
$-0.01
↓ -1325.4% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of 0.25x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↓
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 69 quarters